Recurrence of group B streptococcal infection.
It is clear that the group B streptococcus has become a major pathogen of young infants within the comparatively recent past. Further it is clear that, as with other endemic and epidemic pathogens, increasing clinical and laboratory experience brings to light variations not initially evident. In addition, therapy presumably effective in initial cases may not continue to be so. The following papers by coincidence were received over a relatively brief period of time. Hence, for emphasis of some of the problems related to this organism, they are presented as a group.
D000667:Ampicillin / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000382:microbiology; D004359:Drug Therapy, Combination; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D010400:Penicillin G / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy; D012008:Recurrence; D018805:Sepsis / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy*; D013292:Streptococcus agalactiae / Q000187:drug effects / Q000472:pathogenicity*
D007612:Kanamycin; D000667:Ampicillin; D010400:Penicillin G